MDxHealth SA (NASDAQ:MDXH) Receives Consensus Rating of “Hold” from Analysts

Posted by on Jul 21st, 2026

Shares of MDxHealth SA (NASDAQ:MDXH – Get Free Report) have been given an average rating of “Hold” by the five research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $3.50.

A number of research analysts have recently commented on MDXH shares. Lake Street Capital dropped their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. TD Cowen reiterated a “buy” rating and set a $1.50 price objective (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, BTIG Research cut their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th.

Get Our Latest Stock Report on MDXH

Institutional Investors Weigh In On MDxHealth

Several hedge funds have recently modified their holdings of MDXH. Lazard Asset Management LLC acquired a new stake in shares of MDxHealth during the fourth quarter valued at about $83,000. Jump Financial LLC bought a new stake in shares of MDxHealth during the fourth quarter worth about $139,000. Squarepoint Ops LLC acquired a new position in shares of MDxHealth in the fourth quarter valued at approximately $51,000. Qube Research & Technologies Ltd acquired a new position in shares of MDxHealth in the third quarter valued at approximately $144,000. Finally, Millennium Management LLC bought a new position in MDxHealth in the 3rd quarter valued at approximately $127,000.

MDxHealth Stock Down 1.4%

Shares of MDXH stock opened at $0.42 on Tuesday. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33. The company has a market cap of $20.63 million, a P/E ratio of -0.64 and a beta of 1.43. The business has a fifty day simple moving average of $0.64 and a 200 day simple moving average of $2.19.

MDxHealth (NASDAQ:MDXH – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. As a group, equities research analysts anticipate that MDxHealth will post -0.6 earnings per share for the current fiscal year.

About MDxHealth

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.

Featured Articles

Analyst Recommendations for MDxHealth (NASDAQ:MDXH)

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.